Stocksigma LogoStocksigma Logo

Sheel Biotech Reports Zero Pending Investor Complaints for Q2 FY27

Sheel Biotech Limited submitted its quarterly investor grievance report under Regulation 13(3) of SEBI (LODR) Regulations, 2015, for the quarter ended 30th

Sheel Biotech Reports Zero Pending Investor Complaints for Q2 FY27

Sheel Biotech Ltd 路 Others (Uncategorized) 路 14 Oct 2026, 8:47 pm

Sheel Biotech Reports Zero Pending Investor Complaints for Q2 FY27 Sheel Biotech Limited submitted its quarterly investor grievance report under Regulation 13(3) of SEBI (LODR) Regulations, 2015, for the quarter ended 30th Sep'26. As certified by its Registrar and Share Transfer Agent, Skyline Financial Services Pvt Ltd, the company recorded zero investor complaints pending at the beginning of the quarter, received zero complaints, resolved zero, and closed the period with nil pending complaints across all platforms, including SEBI SCORES, SEBI ODR Portal, and stock exchanges.

Original exchange filing (PDF)

More announcements from Sheel Biotech Ltd

All Sheel Biotech Ltd announcements